Journal of Lipids最新文献_第9页

Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome. 他汀类药物与依折替米贝联合他汀类药物对急性冠脉综合征患者血脂吸收指标的影响

IF 5.3

Journal of Lipids Pub Date : 2015-01-01 Epub Date: 2015-03-01 DOI: 10.1155/2015/109158

Erisa Watanabe, Junichi Yamaguchi, Hiroyuki Arashi, Hiroshi Ogawa, Nobuhisa Hagiwara

{"title":"Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome.","authors":"Erisa Watanabe, Junichi Yamaguchi, Hiroyuki Arashi, Hiroshi Ogawa, Nobuhisa Hagiwara","doi":"10.1155/2015/109158","DOIUrl":"https://doi.org/10.1155/2015/109158","url":null,"abstract":"Background. The use of statins is essential for aggressive lipid-lowering treatment in acute coronary syndrome (ACS) patients with dyslipidemia. Recently, elevation of sitosterol, a lipid absorption marker, was reported to be associated with premature atherosclerosis. The purpose of the present study was to examine the impact of ezetimibe, a selective intestinal cholesterol transporter inhibitor, in ACS patients. Methods. A total of 197 ACS patients were randomized to pitavastatin + ezetimibe (n = 100) or pitavastatin (n = 97). Low-density lipoprotein cholesterol (LDL-C) and sitosterol levels were evaluated on admission and after 12 weeks. Results. After 12 weeks, the pitavastatin + ezetimibe group showed a significantly greater decrease of sitosterol (baseline versus after 12 weeks; 2.9 ± 2.5 versus 1.7 ± 1.0 ng/mL, P < 0.001) than the pitavastatin group (2.7 ± 1.5 versus 3.0 ± 1.4 ng/mL). The baseline sitosterol level was significantly higher in patients with achieved LDL-C levels ≥ 70 mg/dL than in patients with levels < 70 mg/dL (3.2 ± 2.5 versus 2.4 ± 1.3 ng/mL, P = 0.006). Conclusions. Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was a predictor of poor response to aggressive lipid-lowering treatment in ACS patients. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2015 ","pages":"109158"},"PeriodicalIF":5.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/109158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33046997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Emerging risk biomarkers in cardiovascular diseases and disorders. 心血管疾病和失调的新兴风险生物标志物。

IF 5.3

Journal of Lipids Pub Date : 2015-01-01 Epub Date: 2015-04-08 DOI: 10.1155/2015/971453

Ravi Kant Upadhyay

{"title":"Emerging risk biomarkers in cardiovascular diseases and disorders.","authors":"Ravi Kant Upadhyay","doi":"10.1155/2015/971453","DOIUrl":"10.1155/2015/971453","url":null,"abstract":"Present review article highlights various cardiovascular risk prediction biomarkers by incorporating both traditional risk factors to be used as diagnostic markers and recent technologically generated diagnostic and therapeutic markers. This paper explains traditional biomarkers such as lipid profile, glucose, and hormone level and physiological biomarkers based on measurement of levels of important biomolecules such as serum ferritin, triglyceride to HDLp (high density lipoproteins) ratio, lipophorin-cholesterol ratio, lipid-lipophorin ratio, LDL cholesterol level, HDLp and apolipoprotein levels, lipophorins and LTPs ratio, sphingolipids, Omega-3 Index, and ST2 level. In addition, immunohistochemical, oxidative stress, inflammatory, anatomical, imaging, genetic, and therapeutic biomarkers have been explained in detail with their investigational specifications. Many of these biomarkers, alone or in combination, can play important role in prediction of risks, its types, and status of morbidity. As emerging risks are found to be affiliated with minor and microlevel factors and its diagnosis at an earlier stage could find CVD, hence, there is an urgent need of new more authentic, appropriate, and reliable diagnostic and therapeutic markers to confirm disease well in time to start the clinical aid to the patients. Present review aims to discuss new emerging biomarkers that could facilitate more authentic and fast diagnosis of CVDs, HF (heart failures), and various lipid abnormalities and disorders in the future. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2015 ","pages":"971453"},"PeriodicalIF":5.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33161945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated Phospholipid Transfer Protein in Subjects with Multiple Sclerosis. 多发性硬化症患者磷脂转移蛋白升高。

IF 5.3

Journal of Lipids Pub Date : 2015-01-01 Epub Date: 2015-08-12 DOI: 10.1155/2015/518654

Roy A Garvin

{"title":"Elevated Phospholipid Transfer Protein in Subjects with Multiple Sclerosis.","authors":"Roy A Garvin","doi":"10.1155/2015/518654","DOIUrl":"https://doi.org/10.1155/2015/518654","url":null,"abstract":"An anomaly in the plasma proteins of patients with multiple sclerosis detectable on SDS-PAGE has been reported. The molecular weight of the anomaly was the same as the phospholipid transfer protein. A metabolic protein was involved in lipid homeostasis and remodeling of the high density lipoproteins. We have identified the anomaly as the phospholipid transfer protein by western blot using antiphospholipid transfer antibodies. Activity assays showed that the phospholipid transfer activity was elevated in fasted plasma samples from subjects with MS compared to controls. Sequence analysis of the gene encoding the phospholipid transfer protein did not identify any mutations in the genetic structure, suggesting that the increase in activity was not due to structural changes in the protein, but may be due to one of the other proteins with which it forms active complexes. Altered phospholipid transfer activity is important because it could be implicated in the decreased lipid uptake and abnormal myelin lipids observed in multiple sclerosis. It has been shown that alteration in myelin lipid content is an epitope for autoimmunity. Therefore, lipid changes due to a defect in phospholipid transfer and/or uptake could potentially influence the course of the disease. Further research is needed to elucidate the role of the phospholipid transfer protein in subjects with multiple sclerosis. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2015 ","pages":"518654"},"PeriodicalIF":5.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/518654","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34052252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Role of Inositol Phosphosphingolipid Phospholipase C1, the Yeast Homolog of Neutral Sphingomyelinases in DNA Damage Response and Diseases. 中性鞘磷脂酶酵母同源物肌醇磷脂磷脂酶C1在DNA损伤反应和疾病中的作用。

IF 5.3

Journal of Lipids Pub Date : 2015-01-01 Epub Date: 2015-08-06 DOI: 10.1155/2015/161392

Kaushlendra Tripathi

{"title":"Role of Inositol Phosphosphingolipid Phospholipase C1, the Yeast Homolog of Neutral Sphingomyelinases in DNA Damage Response and Diseases.","authors":"Kaushlendra Tripathi","doi":"10.1155/2015/161392","DOIUrl":"https://doi.org/10.1155/2015/161392","url":null,"abstract":"Sphingolipids play a very crucial role in many diseases and are well-known as signaling mediators in many pathways. Sphingolipids are produced during the de novo process in the ER (endoplasmic reticulum) from the nonsphingolipid precursor and comprise both structural and bioactive lipids. Ceramide is the central core of the sphingolipid pathway, and its production has been observed following various treatments that can induce several different cellular effects including growth arrest, DNA damage, apoptosis, differentiation, and senescence. Ceramides are generally produced through the sphingomyelin hydrolysis and catalyzed by the enzyme sphingomyelinase (SMase) in mammals. Presently, there are many known SMases and they are categorized into three groups acid SMases (aSMases), alkaline SMases (alk-SMASES), and neutral SMases (nSMases). The yeast homolog of mammalians neutral SMases is inositol phosphosphingolipid phospholipase C. Yeasts generally have inositol phosphosphingolipids instead of sphingomyelin, which may act as a homolog of mammalian sphingomyelin. In this review, we shall explain the structure and function of inositol phosphosphingolipid phospholipase C1, its localization inside the cells, mechanisms, and its roles in various cell responses during replication stresses and diseases. This review will also give a new basis for our understanding for the mechanisms and nature of the inositol phosphosphingolipid phospholipase C1/nSMase. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2015 ","pages":"161392"},"PeriodicalIF":5.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/161392","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33983996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome. 补充苦瓜对肥胖及代谢综合征相关并发症的有益作用。

IF 5.3

Journal of Lipids Pub Date : 2015-01-01 Epub Date: 2015-01-12 DOI: 10.1155/2015/496169

Md Ashraful Alam, Riaz Uddin, Nusrat Subhan, Md Mahbubur Rahman, Preeti Jain, Hasan Mahmud Reza

{"title":"Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.","authors":"Md Ashraful Alam, Riaz Uddin, Nusrat Subhan, Md Mahbubur Rahman, Preeti Jain, Hasan Mahmud Reza","doi":"10.1155/2015/496169","DOIUrl":"https://doi.org/10.1155/2015/496169","url":null,"abstract":"Diabetes, obesity, and metabolic syndrome are becoming epidemic both in developed and developing countries in recent years. Complementary and alternative medicines have been used since ancient era for the treatment of diabetes and cardiovascular diseases. Bitter melon is widely used as vegetables in daily food in Bangladesh and several other countries in Asia. The fruits extract of bitter melon showed strong antioxidant and hypoglycemic activities in experimental condition both in vivo and in vitro. Recent scientific evaluation of this plant extracts also showed potential therapeutic benefit in diabetes and obesity related metabolic dysfunction in experimental animals and clinical studies. These beneficial effects are mediated probably by inducing lipid and fat metabolizing gene expression and increasing the function of AMPK and PPARs, and so forth. This review will thus focus on the recent findings on beneficial effect of Momordica charantia extracts on metabolic syndrome and discuss its potential mechanism of actions. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2015 ","pages":"496169"},"PeriodicalIF":5.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/496169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33353033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 102

Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. 脂质分离术治疗家族性高胆固醇血症的有效性。

IF 5.3

Journal of Lipids Pub Date : 2014-01-01 Epub Date: 2014-10-19 DOI: 10.1155/2014/864317

Matthew Lui, Ross Garberich, Craig Strauss, Thomas Davin, Thomas Knickelbine

{"title":"Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia.","authors":"Matthew Lui, Ross Garberich, Craig Strauss, Thomas Davin, Thomas Knickelbine","doi":"10.1155/2014/864317","DOIUrl":"https://doi.org/10.1155/2014/864317","url":null,"abstract":"Lipid apheresis is used to treat patients with severe hyperlipidemia by reducing low-density lipoprotein cholesterol (LDL-C). This study examines the effect of apheresis on the lipid panel and cardiac event rates before and after apheresis. An electronic health record screen of ambulatory patients identified 11 active patients undergoing lipid apheresis with 10/11 carrying a diagnosis of FH. Baseline demographics, pre- and postapheresis lipid levels, highest recorded LDL-C, cardiac events, current medications, and first apheresis treatment were recorded. Patients completed a questionnaire and self-reported risk factors and interest in alternative treatment. There were significant reductions in mean total cholesterol (-58.4%), LDL-C (-71.9%), triglycerides (-51%), high-density lipoprotein (HDL) cholesterol (-9.3%), and non-HDL (-68.2%) values. Thirty-four cardiac events were documented in 8 patients before apheresis, compared with 9 events in 5 patients after apheresis. Our survey showed a high prevalence of statin intolerance (64%), with the majority (90%) of participants indicating an interest in alternative treatment options. Our results have shown that lipid apheresis primary effect is a marked reduction in LDL-C cholesterol levels and may reduce the recurrence of cardiac events. Apheresis should be compared to the newer alternative treatment modalities in a randomized fashion due to patient interest in alternative options. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2014 ","pages":"864317"},"PeriodicalIF":5.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/864317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32806169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Spice up your life: adipose tissue and inflammation. 为您的生活增添色彩：脂肪组织与炎症。

IF 5.3

Journal of Lipids Pub Date : 2014-01-01 Epub Date: 2014-02-20 DOI: 10.1155/2014/182575

Anil K Agarwal

引用次数: 0

Why fish oil fails: a comprehensive 21st century lipids-based physiologic analysis. 为什么鱼油不起作用:一个全面的21世纪基于脂质的生理分析。

IF 5.3

Journal of Lipids Pub Date : 2014-01-01 Epub Date: 2014-01-16 DOI: 10.1155/2014/495761

B S Peskin

{"title":"Why fish oil fails: a comprehensive 21st century lipids-based physiologic analysis.","authors":"B S Peskin","doi":"10.1155/2014/495761","DOIUrl":"https://doi.org/10.1155/2014/495761","url":null,"abstract":"The medical community suffered three significant fish oil failures/setbacks in 2013. Claims that fish oil's EPA/DHA would stop the progression of heart disease were crushed when The Risk and Prevention Study Collaborative Group (Italy) released a conclusive negative finding regarding fish oil for those patients with high risk factors but no previous myocardial infarction. Fish oil failed in all measures of CVD prevention-both primary and secondary. Another major 2013 setback occurred when fish oil's DHA was shown to significantly increase prostate cancer in men, in particular, high-grade prostate cancer, in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) analysis by Brasky et al. Another monumental failure occurred in 2013 whereby fish oil's EPA/DHA failed to improve macular degeneration. In 2010, fish oil's EPA/DHA failed to help Alzheimer's victims, even those with low DHA levels. These are by no means isolated failures. The promise of fish oil and its so-called active ingredients EPA / DHA fails time and time again in clinical trials. This lipids-based physiologic review will explain precisely why there should have never been expectation for success. This review will focus on underpublicized lipid science with a focus on physiology. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2014 ","pages":"495761"},"PeriodicalIF":5.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/495761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32137841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. 泰国人群血脂异常患病率及管理，国家健康调查IV, 2009。

IF 5.3

Journal of Lipids Pub Date : 2014-01-01 Epub Date: 2014-03-30 DOI: 10.1155/2014/249584

Wichai Aekplakorn, Surasak Taneepanichskul, Pattapong Kessomboon, Virasakdi Chongsuvivatwong, Panwadee Putwatana, Piyamitr Sritara, Somkiat Sangwatanaroj, Suwat Chariyalertsak

{"title":"Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009.","authors":"Wichai Aekplakorn, Surasak Taneepanichskul, Pattapong Kessomboon, Virasakdi Chongsuvivatwong, Panwadee Putwatana, Piyamitr Sritara, Somkiat Sangwatanaroj, Suwat Chariyalertsak","doi":"10.1155/2014/249584","DOIUrl":"https://doi.org/10.1155/2014/249584","url":null,"abstract":"This study determined the prevalence and management of dyslipidemia in Thai adults using data from the Thai National Health Examination Survey IV in 2009. Dyslipidemia was defined based on the Third Adult Treatment Panel guidelines. A total of 19,021 adults aged 20 yr and over were included. Mean (SE) levels of total cholesterol, HDL-C, LDL-C, and triglycerides were 206.4 (1.03), 46.9 (0.34), 128.7 (1.09), and 131.4 (2.20) mg/dL, respectively. Prevalence of high LDL-C, low HDL-C, and high triglycerides were 29.6 %, 47.1 %, and 38.6%, respectively. Compared with individuals in the north and northeast, residents in Bangkok and Central region had significant higher levels of LDL-C but lower level of HDL-C. Triglyceride level was the highest in the northeast residents. Overall, 66.5% of Thais had some forms of dyslipidemia. Awareness and treatment of high LDL-C among those with high LDL-C were 17.8% and 11.7%, respectively. Among individuals aware of high LDL-C, those at highest CHD risk compared with those at low risk had higher percentage of treatment (73.1% versus 51.7%, resp.) but lower percentage of control at goal (32.9% versus 76.4%, resp.). Various forms of dyslipidemia are common in Thai adults, with a low level of awareness and treatment of high LDL-C. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2014 ","pages":"249584"},"PeriodicalIF":5.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/249584","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32319038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 54

Comparison of carotid intima-media thickness in pediatric patients with metabolic syndrome, heterozygous familial hyperlipidemia and normals. 代谢综合征、杂合子家族性高脂血症与正常儿童颈动脉内膜-中膜厚度的比较。

IF 5.3

Journal of Lipids Pub Date : 2014-01-01 Epub Date: 2014-05-14 DOI: 10.1155/2014/546863

Arvind Vijayasarathi, Stanley J Goldberg

{"title":"Comparison of carotid intima-media thickness in pediatric patients with metabolic syndrome, heterozygous familial hyperlipidemia and normals.","authors":"Arvind Vijayasarathi, Stanley J Goldberg","doi":"10.1155/2014/546863","DOIUrl":"https://doi.org/10.1155/2014/546863","url":null,"abstract":"Background. Our goal was to compare the carotid intimal-medial thickness (CIMT) of untreated pediatric patients with metabolic syndrome (MS), heterozygous familial hyperlipidemia (heFH), and MS+heFH against one another and against a control group consisting of healthy, normal body habitus children. Methods. Our population consisted of untreated pediatric patients (ages 5-20 yrs) who had CIMT measured in a standardized manner. Results. Our population included 57 with MS, 23 with heFH, and 10 with MS+heFH. The control group consisted of 84 children of the same age range. Mean CIMT for the MS group was 469.8 μ m (SD = 67), 443.8 μ m (SD = 61) for the heFH group, 478.3 μ m (SD = 70) for the MS+heFH group, and 423.2 μ m (SD = 45) for the normal control group. Significance differences between groups occurred for heFH versus MS (P = 0.022), heFH versus control (P = 0.038), MS versus control (P = 9.0E - 10), and MS+heFH versus control (P = 0.003). Analysis showed significant negative correlation between HDL and CIMT (r = -0.32, P = 0.03) but not for LDL, triglycerides, BP, waist circumference, or BMI. Conclusion. For pediatric patients, the thickest CIMT occurred for patients with MS alone or for those with MS+heFH. This indicates that MS, rather than just elevated LDL, accounts for more rapid thickening of CIMT in this population. ","PeriodicalId":16274,"journal":{"name":"Journal of Lipids","volume":"2014 ","pages":"546863"},"PeriodicalIF":5.3,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/546863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32447485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8